Name: IGF-1 LR3
Brand: Amino Club
SKU: IGF-1 LR3 - 1MG
Availability: InStock
Rating: 4.8 (69 reviews)

IGF-1 LR3 | 99%+ Pure Peptide | Amino Club | Amino Club

How IGF-1 LR3 Works

Enhanced Growth Factor Signaling

Modified for Maximum Bioactivity

IGF-1 LR3 is a synthetic analog of human insulin-like growth factor 1 with two key modifications: an arginine substitution at position 3 (instead of glutamic acid) and an additional 13 amino acids at the N-terminus. These changes reduce binding to IGF-binding proteins (IGFBPs) while maintaining full agonist activity at the IGF-1 receptor, resulting in enhanced potency and prolonged half-life.

IGF-1RFull Agonist

IGF-1 Receptor

Insulin-like Growth Factor 1 Receptor

Activates PI3K/Akt signaling
Stimulates mTOR pathway
Promotes protein synthesis

IGFBPVery Low Affinity

Reduced IGFBP Binding

Insulin-like Growth Factor Binding Proteins

Bypasses sequestration by binding proteins
Increased free/bioactive fraction
Extended duration of action

Akt/mTOREnhanced

Downstream Signaling

Protein Kinase B / Mammalian Target of Rapamycin

Protein synthesis activation
Cell proliferation and growth
Anti-apoptotic signaling

Tomas et al., J Endocrinol 1996

Key Modification

Why the N-Terminal Extension Matters

Native IGF-1 is rapidly sequestered by six different IGF-binding proteins (IGFBP-1 through 6), which regulate its bioavailability. The 13-amino acid N-terminal extension in IGF-1 LR3 dramatically reduces this binding, allowing more free peptide to reach target tissues.

Result: IGF-1 LR3 retains full pharmacological activity at the IGF-1 receptor while having very low affinity for IGFBPs. This translates to approximately 3-fold greater potency and a half-life of 20-30 hours (vs 12-15 hours for native IGF-1).

Native IGF-1 amino acids70

IGF-1 LR3 amino acids83

Native IGF-1 half-life~12-15 hours

IGF-1 LR3 half-life~20-30 hours

IGFBP Evasion

Bypassing the Regulatory System

In circulation, IGFBPs bind and sequester native IGF-1, limiting its bioavailability. LR3 modification allows the peptide to bypass this regulation.

Clinical significance: Because IGF-1 LR3 is not sequestered by binding proteins, a greater proportion of the administered dose remains bioactive. This is why it demonstrates 2.5-3× greater potency in preclinical models despite binding to the IGF-1 receptor with similar affinity.

Frequently Asked Questions

Common questions about IGF-1 LR3 research

IGF-1 LR3 differs from native IGF-1 in two key ways: it has an arginine instead of glutamic acid at position 3, and it has an additional 13 amino acids (MFPAMPLLSLFVN) at the N-terminus, for a total of 83 amino acids versus 70 for native IGF-1. These modifications dramatically reduce binding to the six IGF-binding proteins (IGFBPs) while maintaining full agonist activity at the IGF-1 receptor. The result is approximately 3-fold greater potency and an extended half-life of 20-30 hours (vs 12-15 hours for native IGF-1).

In circulation, IGFBPs bind and sequester native IGF-1, limiting the amount of free/bioactive peptide available to activate IGF-1 receptors. By reducing IGFBP binding, IGF-1 LR3 remains bioactive longer and a greater proportion of the administered dose reaches target tissues. Studies show that continuous infusion of IGF-1 LR3 was 1.5-2 fold more potent than native IGF-1 for effects on body weight, organ weights, and feed efficiency in animal models.

No. All available research on IGF-1 LR3 comes from preclinical animal studies, primarily in rats. No human clinical trials have been conducted to establish safety, efficacy, or appropriate dosing in humans. The compound remains strictly a research tool and is not approved for human use by any regulatory agency.

In dexamethasone-induced catabolic rats, IGF-1 LR3 was approximately 2.5-fold more potent than native IGF-1 in reversing weight loss and preserving nitrogen balance. The highest dose produced a 6g body weight increase over 7 days (compared to 19g loss in untreated controls). It also increased gut weight by up to 45% and reduced 3-methylhistidine excretion (a protein breakdown marker) by 3-fold more than native IGF-1.

Yes. IGF-1 LR3 is listed on the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). It is prohibited both in-competition and out-of-competition in all sports. Athletes subject to drug testing should be aware that use of this compound will result in a positive test and potential sanctions.

Like most peptides, IGF-1 LR3 in lyophilized (powder) form should be stored at 2-8°C (refrigerated) or -20°C (frozen) for long-term storage. Once reconstituted with bacteriostatic water, it should be kept refrigerated and used within 2-4 weeks. Avoid repeated freeze-thaw cycles and protect from light.

While human safety data is lacking, potential risks based on IGF-1 biology and animal observations include: hypoglycemia (low blood sugar due to insulin-like effects), organ hypertrophy (particularly gut, spleen, kidneys), fluid retention, and theoretical concerns about promoting cancer cell growth. Because IGF-1 LR3 is 2.5-3× more potent than native IGF-1, these effects may be amplified. No long-term safety data exists.

IGF-1 LR3

Modified for Maximum Bioactivity

IGF-1 Receptor

Reduced IGFBP Binding

Downstream Signaling

Why the N-Terminal Extension Matters

Bypassing the Regulatory System

Anabolic Potency Comparison

Key Research Outcomes

IGF-1 LR3 vs Native IGF-1

Protein Synthesis & Anti-Catabolism

Organ & Tissue Effects

Cognitive Research

Catabolic State Reversal

Hypoglycemia risk

Organ hypertrophy

Fluid retention

Joint/muscle pain

Enhanced Potency Considerations

Preclinical Safety Summary

Theoretical Contraindications

💡Researcher Notes

What Is IGF-1 LR3?

How It Differs from Native IGF-1

Where It Stands

What is the difference between IGF-1 LR3 and native IGF-1?

Why does reduced IGFBP binding make IGF-1 LR3 more potent?

Has IGF-1 LR3 been tested in humans?

What were the main findings in animal studies?

Is IGF-1 LR3 banned in sports?

How should IGF-1 LR3 be stored?

What are the potential risks of IGF-1 LR3?

Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats

Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection

IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms

IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype

Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig

⚠️Important Research Notice

All the research peptides you need, with the peace of mind and research community at your fingertips.

Stay Updated with Amino Club

Researcher Notes